| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6114584 | Autoimmunity Reviews | 2015 | 4 Pages |
Abstract
In conclusion, the development and use of biosimilars represent a tool for increasing health system sustainability. However it is of paramount importance to distinguish between the pharmacodynamics of a given drug and its immunogenicity being the two aspects unrelated. Thus a detailed definition of “secondary naïve” patients is challenging, and may be related to both the two parameters.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Martina Biggioggero, Marco Danova, Umberto Genovese, Francesco Locatelli, Pier Luigi Meroni, Fabrizio Pane, Francesco Scaglione,